offline
Sarepta Therapeutics verlieren heute gute 50%:
Is Sarepta Stock Worth Buying After the 50% Plunge? Analyst Weighs In
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only a buck or two, while getting a biotech company wrong can hurt a lot more than that. Case in point: Sarepta Therapeutics (SRPT) shares tanked ~50% in Friday's trading session, following the release of underwhelming clinical trial results.
Specifically, top-line data from the first part study evaluating SRP-9001, the company's microdystrophin gene therapy, for Duchenne muscular dystrophy (DMD) patients, failed to show a statistically meaningful improvement when compared to the placebo.
...
https://finance.yahoo.com/news/sarepta-s...53113.html
![[Bild: SRPTd132925000i.png]](https://finviz.com/publish/010821/SRPTd132925000i.png)
Is Sarepta Stock Worth Buying After the 50% Plunge? Analyst Weighs In
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only a buck or two, while getting a biotech company wrong can hurt a lot more than that. Case in point: Sarepta Therapeutics (SRPT) shares tanked ~50% in Friday's trading session, following the release of underwhelming clinical trial results.
Specifically, top-line data from the first part study evaluating SRP-9001, the company's microdystrophin gene therapy, for Duchenne muscular dystrophy (DMD) patients, failed to show a statistically meaningful improvement when compared to the placebo.
...
https://finance.yahoo.com/news/sarepta-s...53113.html
__________________
